Ticker Details
Alkermes plc Ordinary Shares Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
IPO Date:	August 1, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.27B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 1.86%
Avg Daily Range (30 D):	$0.45 | 1.38%
Avg Daily Range (90 D):	$0.50 | 1.64%

Institutional Daily Volume
Avg Daily Volume:	1.08M
Avg Daily Volume (30 D):	1.59M
Avg Daily Volume (90 D):	1.79M

Trade Size
Avg Trade Size (Sh.):	115
Avg Trade Size (Sh.) (30 D):	68
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	14,059
Avg Institutional Trade:	$2.56M
Avg Institutional Trade (30 D):	$3.92M
Avg Institutional Trade (90 D):	$3.45M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.36M
Avg Closing Trade (30 D):	$11.48M
Avg Closing Trade (90 D):	$10.32M
Avg Closing Volume:	181.52K

News

Feb 23, 2026 @ 3:26 PM Viridian Therapeutics Stock Up 75%, but One Fund J... Source: Jonathan Ponciano

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Feb 10, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces Outcome of the Co... Source: Globe Newswire

Jan 12, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces that Avadel Share... Source: Globe Newswire

Dec 3, 2025 @ 9:47 PM Announcement relating to despatch of Definitive Pr... Source: Globe Newswire

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$2.07	$.5	$.53
Diluted EPS	$2.01	$.49	$.52
Revenue	$1.52B	$394.19M	$390.66M
Gross Profit	$1.31B	$342.59M	$341.2M
Net Income / Loss	$338.83M	$82.76M	$87.1M
Operating Income / Loss	$358.54M	$89.08M	$92.98M
Cost of Revenue	$212.36M	$51.59M	$49.46M
Net Cash Flow	$220.16M	$95.25M	$121.39M
PE Ratio	16.92

Splits
May 15, 2000	2:1